Purpose: The goal of our analysis was to study pretherapeutic circulating 25-OHD plasma levels in patients with previously untreated advanced gastric cancer treated in the randomised controlled phase III Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) trial (NCT00678535) and to explore whether low 25-OHD plasma levels are associated with worse prognosis and may compromise the clinical efficacy of cetuximab.
Methods: Six hundred thirty patients with available pretherapeutic 25-OHD plasma levels and treated with chemotherapy based on capecitabine and cisplatin, or chemotherapy and cetuximab, were included. The Cox proportional hazard regression model was used to analyse the association between low 25-OHD and survival in both treatment arms.
Results: Majority of study patients were found to have severe vitamin D deficiency. No prognostic impact of 25-OHD plasma levels could be found in our patient cohort, and there was no indication of an interference of 25-OHD plasma levels and the efficacy of treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
Conclusions: Although majority of patients with advanced gastric cancer show hypovitaminosis D deficiency, there is no proof for a negative impact on survival or reduced treatment response. A prospective study is needed to investigate the potential benefit of vitamin D supplementation in this patient cohort during first-line chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2019.05.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antioxidant vitamins supplementation reduce endometriosis related pelvic pain in humans: a systematic review and meta-analysis.
Reprod Biol Endocrinol
August 2023
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, People's Republic of China.
Article Synopsis
- The study investigated the impact of antioxidant vitamin supplementation, specifically vitamins C, E, and D, on pain related to endometriosis.
- A systematic review of 13 randomized controlled trials (RCTs) including 589 patients was conducted to analyze pain alleviation using the Visual Analogue Scale (VAS).
- Results showed that vitamin E supplementation effectively reduced clinical pelvic pain, while vitamin D's effect was not statistically significant, and improvements in oxidative stress markers were also noted post-supplementation.
Vitamin D Deficit as Inducer of Adenotonsillar Hypertrophy in Children with Obstructive Sleep Apnea-A Prospective Case-Control Study.
Children (Basel)
January 2023
Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy.
(1) Objective: This prospective case-control study aimed to assess the level of serum vitamin D comparing pediatric non-allergic patients with obstructive sleep apnea (OSA) and healthy controls. (2) Methods: The period of the enrollment was from November 2021 to February 2022. Children with uncomplicated OSA caused by adenotonsillar hypertrophy (ATH) were recruited.
View Article and Find Full Text PDFEffects of maternal and offspring treatment with two dietary sources of vitamin D on the mineral homeostasis, bone metabolism and locomotion of offspring fed protein- and phosphorus-reduced diets.
Arch Anim Nutr
February 2023
Institute of Animal Nutrition, Nutrition Diseases and Dietetics, Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany.
The present study aims to compare the effects of maternal and offspring treatment with 25-hydroxycholecalciferol (25-OHD) and vitamin D on vitamin D status, mineral homoeostasis, bone metabolism and locomotion in the offspring. Either vitamin D (50 μg/kg diet) or 25-OHD (50 μg/kg diet) was supplemented to the gestation and lactation diets of 49 multiparous sows and/or to the diets of their growing offspring. Treatment of the sows did not affect plasma concentrations of 25-OHD of the offspring.
View Article and Find Full Text PDFOff-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience.
Front Pediatr
August 2022
Centre de Référence des Maladies Rares du Calcium et du Phosphore, Centre de Référence des Maladies Rénales Rares, Filières de Santé Maladies Rares OSCAR, ORKID et ERKNet, Service de Néphrologie Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, Bron, France.
Article Synopsis
- - The study analyzed the use of cinacalcet, a medication for primary hyperparathyroidism (PHPT), in 18 pediatric patients from seven French hospitals, highlighting its effectiveness in managing the condition despite some risks.
- - Results showed significant reductions in parathyroid hormone (PTH) and calcium levels over a follow-up of 2.2 years, with no major side effects reported, although one patient experienced kidney stones.
- - The findings suggest that cinacalcet can be a safe and effective treatment for hypercalcemia in pediatric patients with primary hyperparathyroidism.
Dietary supplementation of 25-hydroxycholecalciferol as an alternative to cholecalciferol in swine diets: A review.
J Anim Physiol Anim Nutr (Berl)
November 2022
Institute of Animal Nutrition, Nutrition Diseases and Dietetics, Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany.
25-hydroxycholecalciferol (25-OHD ) formed via hepatic hydroxylation from vitamin D, cholecalciferol, represents the precursor of the biologically active vitamin D hormone, 1,25-dihydroxyvitamin D. Due to a higher absorption rate and the omission of one hydroxylation, dietary supplementation of 25-OHD instead of vitamin D is considered to be more efficient as plasma concentrations of 25-OHD are increased more pronounced. The present review summarises studies investigating potential beneficial effects on mineral homeostasis, bone metabolism, health status and performance in sows, piglets and fattening pigs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!